VistaGen Therapeutics (VTGN) to Release Quarterly Earnings on Thursday

VistaGen Therapeutics (NASDAQ:VTGN) is expected to be posting its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.3650) per share and revenue of $0.50 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its earnings results on Monday, June 15th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). The firm had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.40 million. VistaGen Therapeutics had a negative return on equity of 133.02% and a negative net margin of 5,487.01%.During the same quarter last year, the firm posted ($1.67) EPS. On average, analysts expect VistaGen Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

VistaGen Therapeutics Stock Up 4.5%

Shares of NASDAQ VTGN opened at $0.24 on Thursday. The stock has a market cap of $9.98 million, a PE ratio of -0.13 and a beta of 0.40. VistaGen Therapeutics has a 52-week low of $0.20 and a 52-week high of $5.14. The business has a 50-day moving average price of $0.45 and a 200 day moving average price of $0.55.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $0.95.

Institutional Investors Weigh In On VistaGen Therapeutics

Several hedge funds have recently made changes to their positions in VTGN. Bank of America Corp DE increased its position in VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after acquiring an additional 19,331 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in VistaGen Therapeutics during the 1st quarter worth approximately $25,000. Marshall Wace LLP acquired a new stake in VistaGen Therapeutics during the 2nd quarter worth approximately $69,000. Jane Street Group LLC purchased a new position in shares of VistaGen Therapeutics in the 2nd quarter valued at approximately $190,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of VistaGen Therapeutics by 56.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 68,017 shares of the company’s stock valued at $241,000 after purchasing an additional 24,655 shares during the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.